This is a demo store. No orders will be fulfilled.

德克拉维替尼(BMS-986165), 酪氨酸蛋白激酶 TYK2 负异位调节剂

JAK抑制剂
有货

库存信息

关闭

库存信息

关闭

库存信息

关闭

库存信息

关闭

库存信息

关闭
货号 (SKU) 包装规格 是否现货 价格 数量
D414239-5mg
5mg 现货 Stock Image
D414239-10mg
10mg 现货 Stock Image
D414239-25mg
25mg 现货 Stock Image
D414239-50mg
50mg 现货 Stock Image
D414239-100mg
100mg 现货 Stock Image

基本描述

英文别名 Deucravacitinib | NSC825520 | compound 11 [PMID: 31318208} | EN300-22276121 | Deucravacitinib [USAN] | (BMS-986165) | SCHEMBL20520348 | Sotyktu | AT18623 | DEUCRAVACITINIB [JAN] | 6-[(Cyclopropylcarbonyl)amino]-4-[[2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3
规格或纯度 Moligand™, ≥98%
英文名称 Deucravacitinib (BMS-986165)
生化机理 Deucravacitinib(BMS-986165)是一种高效、高选择性的 Tyk2 异构体抑制剂,与 Tyk2 伪激酶结构域结合的 Ki 值为 0.02 nM。它对265种激酶和伪激酶具有高度选择性。
储存温度 -20°C储存
运输条件 超低温冰袋运输
作用类型 抑制剂
作用机制 酪氨酸蛋白激酶 TYK2 负异位调节剂
产品介绍

BMS-986165 是一种高选择性、口服生物可利用的变构 TYK2 抑制剂,用于治疗自身免疫性疾病。它通过稳定调节 JH2 结构域来阻断受体介导的 Tyk2 激活,可抑制IL-12/23和 I 型IFN 途径。


Information

Deucravacitinib (BMS-986165) Deucravacitinib (BMS-986165) is a highly potent and selective allosteric inhibitor of Tyk2 with a Ki value of 0.02 nM for binding to the Tyk2 pseudokinase domain. It is highly selective against a panel of 265 kinases and pseudokinases.


Targets

Tyk2 (Cell-free assay) 0.02 nM


In vitro

BMS-986165 is highly differentiated from all other reported JAK/TYK2 inhibitors due to its ability to achieve an unprecedented level of selectivity for TYK2, especially over JAK1, JAK2, and JAK3.


In vivo

BMS-986165 has been identified as a highly potent and selective allosteric TYK2 inhibitor having excellent PK properties across species with minimal profiling liabilities and is orally efficacious with dose-dependent activity in a murine disease model of psoriasis. Significant activity has also been observed with 11 in other murine autoimmune disease models of colitis and lupus.


Cell Research(from reference)

Cell lines:CD3+ T-cells, CD161+ CD3+ T-cells, TF-1 cells, mononuclear cells, platelets 

Concentrations:0 - 10 μM 

纯度 ≥98%

产品属性

ALogP 1.2

关联靶点(人)

TYK2 Tclin 非受体酪氨酸蛋白激酶 TYK2(Non-receptor tyrosine-protein kinase TYK2) (11 活性数据)
活性类型 活性值-log(M) 作用机制 期刊 参考文献(PubMed IDs)
JAK1 Tclin 酪氨酸蛋白激酶JAK1(Tyrosine-protein kinase JAK1) (1 活性数据)
活性类型 活性值-log(M) 作用机制 期刊 参考文献(PubMed IDs)
BMPR2 Tchem 骨形态发生蛋白受体 2 型(Bone morphogenetic protein receptor type-2) (0 活性数据)
活性类型 活性值-log(M) 作用机制 期刊 参考文献(PubMed IDs)
KCNH2 Tclin HERG (29587 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
JAK3 Tclin Tyrosine-protein kinase JAK3 (8349 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
JAK1 Tclin Tyrosine-protein kinase JAK1 (8569 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
JAK2 Tclin Tyrosine-protein kinase JAK2 (12915 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
CYP2D6 Tclin Cytochrome P450 2D6 (33882 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
CYP1A2 Tchem Cytochrome P450 1A2 (26471 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
TYK2 Tclin Tyrosine-protein kinase TYK2 (5029 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
CYP2C9 Tchem Cytochrome P450 2C9 (32119 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
CYP2C19 Tchem Cytochrome P450 2C19 (29246 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
CYP3A4 Tclin Cytochrome P450 3A4 (53859 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
BMPR2 Tchem Bone morphogenetic protein receptor type-2 (640 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
JAK3 Tclin JAK3/JAK1 (270 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
JAK1 Tclin JAK2/JAK1 (79 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID

关联靶点(其它种属)

Mus musculus (284745 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
Tyk2 Non-receptor tyrosine-protein kinase TYK2 (29 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID

作用机制

作用机制 Action Type target ID Target Name Target Type Target Organism Binding Site Name 参考文献

名称和识别符

分子类型 小分子
IIUPAC Name 6-(cyclopropanecarbonylamino)-4-[2-methoxy-3-(1-methyl-1,2,4-triazol-3-yl)anilino]-N-(trideuteriomethyl)pyridazine-3-carboxamide
INCHI 1S/C20H22N8O3/c1-21-20(30)16-14(9-15(25-26-16)24-19(29)11-7-8-11)23-13-6-4-5-12(17(13)31-3)18-22-10-28(2)27-18/h4-6,9-11H,7-8H2,1-3H3,(H,21,30)(H2,23,24,25,29)/i1D3
InChi Key BZZKEPGENYLQSC-FIBGUPNXSA-N
Smiles CNC(=O)C1=NN=C(C=C1NC2=CC=CC(=C2OC)C3=NN(C=N3)C)NC(=O)C4CC4
Isomeric SMILES [2H]C([2H])([2H])NC(=O)C1=NN=C(C=C1NC2=CC=CC(=C2OC)C3=NN(C=N3)C)NC(=O)C4CC4
分子量 425.46
Reaxy-Rn 41849078
Reaxys-RN link address https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=41849078&ln=

化学和物理性质

溶解性 Solubility (25°C) In vitro DMSO: 29 mg/mL (68.16 mM); Water: Insoluble; Ethanol: Insoluble;
分子量 425.500 g/mol
XLogP3 1.200
氢键供体数Hydrogen Bond Donor Count 3
氢键受体数Hydrogen Bond Acceptor Count 8
可旋转键计数Rotatable Bond Count 7
精确质量Exact Mass 425.2 Da
单同位素质量Monoisotopic Mass 425.2 Da
拓扑极表面积Topological Polar Surface Area 136.000 Ų
重原子数Heavy Atom Count 31
形式电荷Formal Charge 0
复杂度Complexity 648.000
同位素原子数Isotope Atom Count 3
定义的原子立体中心计数Defined Atom Stereocenter Count 0
未定义的原子立体中心计数Undefined Atom Stereocenter Count 0
定义的键立体中心计数Defined Bond Stereocenter Count 0
未定义的键立体中心计数Undefined Bond Stereocenter Count 0
所有立体化学键的总数The total count of all stereochemical bonds 0
共价键合单元计数Covalently-Bonded Unit Count 1

质检证书(CoA,COO,BSE/TSE 和分析图谱)

C of A & Other Certificates(BSE/TSE, COO):
输入批号以搜索分析图谱:

通过匹配包装上的批号来查找并下载产品的 COA,每批产品都进行了严格的验证,您可放心使用!

找到10个结果

批号(Lot Number) 证书类型 货号
E2423288 分析证书 D414239
E2423305 分析证书 D414239
E2423296 分析证书 D414239
E2423300 分析证书 D414239
E2423290 分析证书 D414239
E2423294 分析证书 D414239
E2423298 分析证书 D414239
E2423303 分析证书 D414239
E2423307 分析证书 D414239
E2423292 分析证书 D414239

可替换产品

引用文献

1. Schlapbach C, Conrad C.  (2022)  TYK-ing all the boxes in psoriasis..  J Allergy Clin Immunol,  149  (6): (1936-1939).  [PMID:35341877]
2. Papp K, Gordon K, Thaçi D, Morita A, Gooderham M, Foley P, Girgis IG, Kundu S, Banerjee S.  (2018)  Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis..  N Engl J Med,  379  (14): (1313-1321).  [PMID:30205746]
3. Wrobleski ST, Moslin R, Lin S, Zhang Y, Spergel S, Kempson J, Tokarski JS, Strnad J, Zupa-Fernandez A, Cheng L et al..  (2019)  Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165..  J Med Chem,  62  (20): (8973-8995).  [PMID:31318208]
4. Burke JR, Cheng L, Gillooly KM, Strnad J, Zupa-Fernandez A, Catlett IM, Zhang Y, Heimrich EM, McIntyre KW, Cunningham MD et al..  (2019)  Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain..  Sci Transl Med,  11  (502): [PMID:31341059] [10.1126/scitranslmed.aaw1736]
5. Chang Y, Xu S, Ding K.  (2019)  Tyrosine Kinase 2 (TYK2) Allosteric Inhibitors To Treat Autoimmune Diseases..  J Med Chem,  62  (20): (8951-8952).  [PMID:31603320]

溶液计算器